Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ONCY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $47.66M
- EPS (TTM)
- -$0.33
- Dividend yield
- None
- 52-week range
- 0.33 – 1.30
- Day range
- 0.34 – 0.3885
- Volume / Avg
- 1.11M / 1.17M
- Beta
- —
- Shares outstanding
- 136.14M
52-week range
ONCY stock today
Shares of Oncolytics Biotech (ONCY) finished lower on Nov 20 at $0.3501, a drop of 10.37% or $0.0405 per share, versus the S&P 500's 3.70% decline. Shares are 73.1% below their 52-week high of $1.30, set on Jan 22, 2026 and 6.1% above the 52-week low of $0.33, near the bottom of the past year's range. ONCY is down 59.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 65.0%.
Oncolytics Biotech has posted a net loss over the last twelve months (EPS of -$0.33), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Oncolytics Biotech
Company profileOncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Jared Kelly J.D., L.L.M.
- Headquarters
- San Diego, CA
- Employees
- 29
- Website
- oncolyticsbiotech.com
Financial highlights
Full financialsOncolytics Biotech reported a net loss of $28.8 million, compared with a loss of $22.8 million a year earlier. Diluted earnings per share came in at -$0.30.
| Fiscal year | FY 2025 | FY 2024 | FY 2017 | FY 2016 |
|---|---|---|---|---|
| Revenue | — | — | $6.18M | $0 |
| Growth | — | — | — | — |
| Net income | $-28.76M | $-22.79M | — | — |
| EPS (diluted) | $-0.30 | $-0.30 | — | — |
Analyst forecast
ForecastConsensus (6 analysts)
buy
Avg. price target
$4.15+1085.38%
- Strong buy 3
- Buy 2
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.08 vs $-0.07
- Surprise
- -14.29%
ONCY news
All ONCY news- Oncolytics Biotech Inc. Reports Voting Results from 2026 Annual MeetingNasdaq
- Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in SCACGlobeNewswire
- Oncolytics Biotech Inc. Announces Clinical Supply Agreement with Coherus Oncology, Inc.NasdaqONCY, WSO.B
- Oncolytics Partners With Coherus For Testing Pelareorep+LOQTORZI Combination In Anal CarcinomaNasdaqCHRS, ONCY, ET
- Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal CarcinomaGlobeNewswire
- Oncolytics Biotech Inc. Announces Translational Data for Pelareorep in Multiple Myeloma to be Presented at 68th ASH Annual MeetingNasdaq
- Pelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma PatientsGlobeNewswire
- Oncolytics Biotech Inc. Announces Translational Data for Pelareorep at SITC 2026 Annual MeetingNasdaq
Oncolytics Biotech peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RFLRafael Holdings Inc. Class B | 0.9197 | +2.19% | $47.99M | vs ONCY |
| HRTXHeron Therapeutics Inc. | 0.2525 | -4.39% | $48.04M | vs ONCY |
| NMADNomad Power Solutions Inc. | 2.56 | +13.53% | $47.15M | vs ONCY |
| VRCAVerrica Pharmaceuticals Inc. | 2.74 | -5.03% | $47.07M | vs ONCY |
| TNXPTonix Pharmaceuticals Holding Corp. | 2.38 | -6.67% | $46.25M | vs ONCY |
| MISTMilestone Pharmaceuticals Inc. | 0.3711 | -7.06% | $46.20M | vs ONCY |
| HOWLWerewolf Therapeutics Inc. | 0.9466 | -3.97% | $46.00M | vs ONCY |
| ACRVAcrivon Therapeutics Inc. | 1.15 | -17.86% | $49.35M | vs ONCY |
Indexes, lists and sector
Oncolytics Biotech stock FAQ
What is Oncolytics Biotech's stock price today?
ONCY last traded at $0.3501 as of Nov 20, 4:00 PM EST, down 10.37% on the day. Prices are delayed at least 15 minutes.
Does Oncolytics Biotech pay a dividend?
No. Oncolytics Biotech does not currently pay a regular cash dividend.
Who is Oncolytics Biotech's CEO?
Mr. Jared Kelly J.D., L.L.M. is the chief executive officer of Oncolytics Biotech Inc., which has about 29 employees.
Has ONCY ever split its stock?
Yes. The most recent ONCY stock split was a 10-for-95 split on May 25, 2018.
What is the ONCY 52-week high?
The 52-week high for ONCY is $1.30 and the 52-week low is $0.33. The stock is currently 73.1% below its high.